💡 Renal Denervation: A New Era in Hypertension Care 🩺

Despite decades of effective medications, only ~25% of patients worldwide achieve blood pressure control. Non-adherence remains a huge barrier. 📉

This Nature Reviews Cardiology article (Fisher & Kirtane, Sept 2025) explores the journey of renal denervation (RDN) — from Smithwick’s sympathectomy in the 1950s to today’s FDA-approved radiofrequency 🔥 and ultrasound 🔊 catheter systems.

✅ Sham-controlled trials show RDN lowers BP by 5–10 mmHg, similar to one effective antihypertensive drug.

✅ Durable safety profile, up to 10 years in registries.

✅ Best suited for resistant hypertension, drug intolerance, or pill fatigue.

✅ Implementation requires multidisciplinary teams and shared decision-making. 🤝

🚀 Future: Expanding to underrepresented populations, CKD, elderly, and even beyond hypertension (AFib, sleep apnea, metabolic syndrome).

👉 A fascinating example of how history, technology, and evidence converge to reshape cardiovascular medicine.